Atypical clinicopathological features are associated with worse outcomes in anti-HMGCR myopathy

Background and objectives This study aimed to investigate the heterogeneous clinicopathological features and associated prognoses of anti-HMGCR patients with immune-mediated necrotizing myopathy (IMNM). Methods This study enrolled patients with anti-HMGCR-positive detected both by ELISA and Western blotting assays. The clinical, pathological data, and exome sequencing (WES) information of the patients were collected. Patients whose clinical and pathological features met the 2016 European Neuromuscular Centre criteria for IMNM were classified as having typical IMNM. Conversely, patients presenting with atypical clinical manifestations, such as asymptomatic hyperCKemia, muscular dystrophy-like phenotypes, or exhibiting at least one atypical histopathological feature (e.g., ragged red fibers or COX-negative fibers in patients under 60 years old, lipid aggregation, glycogen accumulation, or rimmed vacuoles) were assigned to the atypical IMNM group. Time-to-remission was used to evaluate the prognosis of the patients. Results Seventy-one patients were positive for anti-HMGCR antibodies by preliminary ELISA screening, and 65 patients were confirmed to be anti-HMGCR-positive by Western blotting assay. Fifteen of the 65 patients (23.1%) exhibited atypical IMNM, and no pathogenic mutations were found in these 15 patients by WES. Patients with atypical IMNM had a younger age of onset (29.3 ± 17.5 vs. 49.3 ± 16.6 years; P < 0.0001), no statin exposure (0% vs. 30%, P = 0.014), and more neck flexor weakness (66.7% vs. 34%; P = 0.022). The atypical group exhibited ragged red fibers (13.3%), COX-negative fibers (26.7%) in patients under 60 years old, lipid aggregation (13.3%), glycogen accumulation (20%), and rimmed vacuoles (46.7%). Additionally, patients with atypical IMNM had a longer time to remission (Log-rank P = 0.033) and more frequently experienced chronic continuous courses (60% vs. 20.5%; P = 0.040) compared with the patients with typical IMNM. Conclusion Anti-HMGCR-positive IMNM patients with atypical clinicopathological manifestations had worse prognosis and poor response to treatment compared to those with typical patterns, which suggest these patients may have distinct pathogenesis and need to find novel therapy.

Authors

Institutions

Publication Details

Journal
Orphanet Journal of Rare Diseases
Published
2026-11-18
DOI
https://doi.org/10.1186/s13023-026-04722-7
Primary Topic
Inflammatory Myopathies and Dermatomyositis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Atypical clinicopathological features are associated with worse outcomes in anti-HMGCR myopathy

Qinglin Peng, Hongxia Yang, Wei Jiang, Xiaolan Tian et al.
4 links
Orphanet Journal of Rare Diseases
Inflammatory Myopathies and Dermatomyositis
article

Atypical clinicopathological features are associated with worse outcomes in anti-HMGCR myopathy

Qinglin Peng, Hongxia Yang, Wei Jiang, Xiaolan Tian, Guochun Wang, Wenli Li, Xin Lu, Qingyan Liu, Chao Sun
article en

Abstract

Background and objectives This study aimed to investigate the heterogeneous clinicopathological features and associated prognoses of anti-HMGCR patients with immune-mediated necrotizing myopathy (IMNM). Methods This study enrolled patients with anti-HMGCR-positive detected both by ELISA and Western blotting assays. The clinical, pathological data, and exome sequencing (WES) information of the patients were collected. Patients whose clinical and pathological features met the 2016 European Neuromuscular Centre criteria for IMNM were classified as having typical IMNM. Conversely, patients presenting with atypical clinical manifestations, such as asymptomatic hyperCKemia, muscular dystrophy-like phenotypes, or exhibiting at least one atypical histopathological feature (e.g., ragged red fibers or COX-negative fibers in patients under 60 years old, lipid aggregation, glycogen accumulation, or rimmed vacuoles) were assigned to the atypical IMNM group. Time-to-remission was used to evaluate the prognosis of the patients. Results Seventy-one patients were positive for anti-HMGCR antibodies by preliminary ELISA screening, and 65 patients were confirmed to be anti-HMGCR-positive by Western blotting assay. Fifteen of the 65 patients (23.1%) exhibited atypical IMNM, and no pathogenic mutations were found in these 15 patients by WES. Patients with atypical IMNM had a younger age of onset (29.3 ± 17.5 vs. 49.3 ± 16.6 years; P < 0.0001), no statin exposure (0% vs. 30%, P = 0.014), and more neck flexor weakness (66.7% vs. 34%; P = 0.022). The atypical group exhibited ragged red fibers (13.3%), COX-negative fibers (26.7%) in patients under 60 years old, lipid aggregation (13.3%), glycogen accumulation (20%), and rimmed vacuoles (46.7%). Additionally, patients with atypical IMNM had a longer time to remission (Log-rank P = 0.033) and more frequently experienced chronic continuous courses (60% vs. 20.5%; P = 0.040) compared with the patients with typical IMNM. Conclusion Anti-HMGCR-positive IMNM patients with atypical clinicopathological manifestations had worse prognosis and poor response to treatment compared to those with typical patterns, which suggest these patients may have distinct pathogenesis and need to find novel therapy.

Orphanet Journal of Rare Diseases
Peking University (CN), China-Japan Friendship Hospital (CN), Peking University First Hospital (CN)
Good health and well-being
Inflammatory Myopathies and Dermatomyositis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon